Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 20/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808298 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL30288497 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL22261623 | 1.00 | OPRM1 (0.64) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL25428921 | 0.89 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL25428918 | 0.89 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL22296894 | 0.86 | OPRM1 (0.60) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL22296830 | 0.86 | OPRM1 (0.60) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL29967521 | 0.86 | OPRM1 (0.65) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL26638893 | 0.86 | OPRM1 (0.65) | OPRM1OPRD1OPRK1KCNH2SCN5A | |
| SCHEMBL30286713 | 0.85 | OPRM1 (0.70) | OPRM1OPRD1OPRK1KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265604-A1 | OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-11111236-B2 | Method for preparing oxaspirocycle derivative, and intermediate thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-11111236-B2 | Method for preparing oxaspirocycle derivative, and intermediate thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-20200308151-A1 | METHOD FOR PREPARING OXASPIROCYCLE DERIVATIVE, AND INTERMEDIATE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| US-20200308151-A1 | METHOD FOR PREPARING OXASPIROCYCLE DERIVATIVE, AND INTERMEDIATE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3689859-A1 | METHOD FOR PREPARING OXASPIROCYCLE DERIVATIVE, AND INTERMEDIATE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689859-A1 | METHOD FOR PREPARING OXASPIROCYCLE DERIVATIVE, AND INTERMEDIATE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111236-B2 | Method for preparing oxaspirocycle derivative, and intermediate thereof | DHPS, OSTC, ODC1 | OPRM1 2466/4885OPRD1 1119/4885OPRK1 2013/4885 |
| US-20200308151-A1 | METHOD FOR PREPARING OXASPIROCYCLE DERIVATIVE, AND INTERMEDIATE THEREOF | DHPS, OSTC, ODC1 | OPRM1 2466/4885OPRD1 1119/4885OPRK1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.